Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

BeyondSpring Inc. (BYSI)

0.7465   -0.004 (-0.47%) 09-28 16:00
Open: 0.7262 Pre. Close: 0.75
High: 0.77 Low: 0.7112
Volume: 31,122 Market Cap: 29(M)

Technical analysis

as of: 2023-09-28 4:49:27 PM
Short-term rate:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Mid-term rate:       
Target: Six months: 1     One year: 1.1
Support: Support1: 0.71    Support2: 0.59
Resistance: Resistance1: 0.85    Resistance2: 0.94
Pivot: 0.84
Moving Average: MA(5): 0.76     MA(20): 0.86
MA(100): 1.04     MA(250): 1.24
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 17     %D(3): 17.2
RSI: RSI(14): 33.1
52-week: High: 3.45  Low: 0.54
Average Vol(K): 3-Month: 38 (K)  10-Days: 31 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BYSI ] has closed above bottom band by 15.1%. Bollinger Bands are 38.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.77 - 0.78 0.78 - 0.78
Low: 0.7 - 0.7 0.7 - 0.71
Close: 0.74 - 0.75 0.75 - 0.75

Company Description

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.

Headline News

Thu, 28 Sep 2023
BeyondSpring and Leading Cancer Center to Present Poster at ... - BioSpace

Wed, 20 Sep 2023
DatChat Inc Announces Reverse Stock Split and Focus on Privacy ... - Best Stocks

Thu, 07 Sep 2023
BeyondSpring to Participate in the R.W. Baird's 2023 Global - GlobeNewswire

Tue, 20 Jun 2023
SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson ... - GlobeNewswire

Tue, 18 Apr 2023
BeyondSpring Provides Business Update and Reports Year End ... - GlobeNewswire

Tue, 20 Dec 2022
Individual investors who hold 50% of BeyondSpring Inc. (NASDAQ:BYSI) gained 153%, insiders profited as well - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 39 (M)
% Held by Insiders 2.385e+007 (%)
% Held by Institutions 29.6 (%)
Shares Short 1,970 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -3.701e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -2
Return on Assets (ttm) 756.4
Return on Equity (ttm) -36.5
Qtrly Rev. Growth 1.35e+006
Gross Profit (p.s.) -0.59
Sales Per Share -1826.36
EBITDA (p.s.) 0
Qtrly Earnings Growth -0.9
Operating Cash Flow 0 (M)
Levered Free Cash Flow -27 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow -0.85

Stock Dividends

Dividend 0
Forward Dividend 1.93e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.